← ANALYST RATINGS · TIPRANKS
Zoetis (ZTS): analyst forecast and price target
Analyst consensus
Moderate Buy3 Buy5 Hold0 Sell
Ratings of 8 analysts in the last 3 months · top analysts only12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $89.83, the highest $115, the lowest $80.00. The average is +13.2% from the last price of $79.38.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $115 | Buy | +44.9% | Reiterated | 16.10.26on TipRanks 07:55 | +2.3% | ↗ |
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $78.00 → $84.00+7.7% | Buy | +5.8% | Upgrade | 13.10.26on TipRanks 11:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $76.00 → $82.00+7.9% | Hold | +3.3% | Reiterated | 13.10.26on TipRanks 11:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $78.00 → $84.00+7.7% | Buy | +5.8% | Upgrade | 13.10.26on TipRanks 11:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $77.00 → $83.00+7.8% | Hold | +4.6% | Reiterated | 13.10.26on TipRanks 11:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $78.00 → $84.00+7.7% | Buy | +5.8% | Upgrade | 13.10.26on TipRanks 11:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $81.00 → $84.00+3.7% | Buy | +5.8% | Reiterated | 13.10.26on TipRanks 11:05 | — | |
| Daniel Clark★★★★★★★★★★#3492 · hits 65% · avg +17.4% | Leerink Partners | — | Hold | — | Reiterated | 01.10.26on TipRanks 11:35 | −1.2%next day +0.1% · 5 days +4.5% | ↗ |
| Jonathan Block★★★★★★★★★★#2320 · hits 50% · avg +5.3% | Stifel Nicolaus | — | Hold | — | Reiterated | 18.09.26on TipRanks 07:50 | −2.3%next day −1.6% · 5 days −1.8% | ↗ |
| Steve Scala★★★★★★★★★★#1275 · hits 63% · avg +10.5% | TD Cowen | $104 → $94.00−9.6% | Buy | +18.4% | Assigned | 25.08.26on TipRanks Aug 24 18:30 | −0.2%next day +0.3% · 5 days +0.5% | ↗ |
| Glen Santangelo★★★★★★★★★★#2956 · hits 52% · avg +4.5% | Barclays | $85.00 | Hold | +7.1% | Reiterated | 17.08.26on TipRanks Aug 18 05:25 | −0.6%next day +2.0% · 5 days +6.9% | ↗ |
| Daniel Grosslight★★★★★★★★★★#4007 · hits 47% · avg +3.6% | Citi | $112 → $96.00−14.3% | Buy | +20.9% | Reiterated | 11.08.26on TipRanks Aug 10 16:25 | +1.0%next day −2.7% · 5 days −1.4% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $90.00 → $80.00−11.1% | Hold | +0.8% | Reiterated | 10.08.26on TipRanks 07:16 | +3.0%next day +1.0% · 5 days −2.4% | ↗ |
| Erin Wright★★★★★★★★★★#354 · hits 64% · avg +15.1% | Morgan Stanley | $85.00 | Buy | +7.1% | Assigned | 10.08.26on TipRanks Aug 7 07:50 | −6.6%next day +3.0% · 5 days +1.2% | ↗ |
| Brandon Vazquez★★★★★★★★★★#11688 · hits 42% · avg −5.1% | William Blair | — | Hold | — | Downgrade | 08.08.26on TipRanks Aug 6 12:14 | +4.0%next day −6.6% · 5 days −3.1% | ↗ |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $81.00 → $84.00+3.7% | Hold | +5.8% | Reiterated | 07.08.26on TipRanks 10:05 | — | |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $81.00 → $87.00+7.4% | Buy | +9.6% | Upgrade | 07.08.26on TipRanks 10:05 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $77.00 → $81.00+5.2% | Hold | +2.0% | Reiterated | 07.08.26on TipRanks 10:05 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $83.00 → $87.00+4.8% | Buy | +9.6% | Reiterated | 07.08.26on TipRanks 10:05 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $82.00 → $84.00+2.4% | Hold | +5.8% | Downgrade | 07.08.26on TipRanks 10:05 | — | |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $86.00 → $84.00−2.3% | Hold | +5.8% | Downgrade | 07.08.26on TipRanks 10:00 | — | |
| Andrea Alfonso★★★★★★★★★★#2181 · hits 100% · avg +43.2% | UBS | $85.00 → $80.00−5.9% | Hold | +0.8% | Assigned | 07.08.26on TipRanks 09:10 | −6.6%next day +3.0% · 5 days +1.2% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | — | Hold | — | Reiterated | 28.07.26on TipRanks 11:42 | +0.5%next day +2.1% · 5 days −6.0% | ↗ |
| Sidharth Sahoo★★★★★★★★★★#9090 · hits 43% · avg −0.9% | HSBC | $140 → $95.00−32.1% | Buy | +19.7% | Reiterated | 06.07.26on TipRanks 10:35 | 0.0%next day +1.6% · 5 days +0.2% | ↗ |
| Jasper Hellweg★★★★★★★★★★#2291 · hits 57% · avg +7.4% | Argus Research | — | Hold | — | Downgrade | 26.05.26on TipRanks May 27 07:30 | −2.0%next day −0.9% · 5 days −6.0% | ↗ |
| Scott Schoenhaus★★★★★★★★★★#12104 · hits 35% · avg −9.7% | KeyBanc | — | Hold | — | Reiterated | 08.05.26on TipRanks 05:30 | −6.0%next day −7.7% · 5 days −10.6% | ↗ |
| Thomas DeBourcy★★★★★★★★★★#7610 · hits 100% · avg +34.1% | Nephron | $131 | Hold | +65.0% | Downgrade | 05.03.26on TipRanks 16:25 | +0.7%next day −0.1% · 5 days −3.3% | ↗ |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $160 | Buy | +101.6% | Reiterated | 26.02.26on TipRanks 07:40 | +1.2%next day +1.5% · 5 days −4.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Zoetis
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $91.25 at a price of $69.83 (+30.7%); now: $90.71 at $79.38 (+14.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 1 | 1 | 1 |
| Buy | 1 | 2 | 2 | 4 | 3 | 3 |
| Hold | 8 | 10 | 11 | 12 | 10 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.51 (from $1.44 to $1.61). Last quarter: $1.87.
Sales
Next quarter’s sales estimate — $2.3B (from $2.3B to $2.3B). Last quarter: $2.5B.
Best top-analyst consensus in the sector · Healthcare
About Zoetis
- CEO: Kristin C. Peck
- Employees: 14,500
- 10 Sylvan Way, Parsippany, NJ, 07054, US
- www.zoetis.com
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, th
Data from the stock’s TipRanks forecast page, read 45 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗